Related references
Note: Only part of the references are listed.2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)
Juhani Knuuti et al.
EUROPEAN HEART JOURNAL (2020)
Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents A Meta-Analysis
Thomas A. Mavrakanas et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Drug-eluting compared to bare metal stents in patients with end-stage renal disease on dialysis: a meta-analysis
Vincenzo Alessandro Galiffa et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2019)
Extended Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
Charles E. Howard et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
Practical issues in clinical scenarios ID involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations
Adrian Covic et al.
BMC MEDICINE (2018)
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease
Juan-Jesus Carrero et al.
KIDNEY INTERNATIONAL (2017)
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis
Yung-Tai Chen et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI
Gennaro Giustino et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Coronary Revascularization in Patients with CKD Stage 5D: Pragmatic Considerations
Gautam R. Shroff et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Dialysis Patients with Implanted Drug-Eluting Stents Have Lower Major Cardiac Events and Mortality than Those with Implanted Bare-Metal Stents: A Taiwanese Nationwide Cohort Study
Hsin-Fu Lee et al.
PLOS ONE (2016)
Are at Least 12 Months of Dual Antiplatelet Therapy Needed for All Patients With Drug-Eluting Stents? Not All Patients With Drug-Eluting Stents Need at Least 12 Months of Dual Antiplatelet Therapy
Richard C. Becker et al.
CIRCULATION (2015)
Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease
Omar K. Siddiqi et al.
HEART (2015)
United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease
Allan J. Collins et al.
KIDNEY INTERNATIONAL SUPPLEMENTS (2015)
Anticoagulation in chronic kidney disease patients-the practical aspects
Stephen Hughes et al.
CLINICAL KIDNEY JOURNAL (2014)
Antithrombotic Therapy in Patients With Chronic Kidney Disease
Davide Capodanno et al.
CIRCULATION (2012)
Chronic kidney disease - Effects on the cardiovascular system
Ernesto L. Schiffrin et al.
CIRCULATION (2007)
Optimal medical therapy with or without PCI for stable coronary disease
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: An angiographic examination
T Ohtake et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Share Paper
